Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2021 Financial Results and Provide Business Update

Rhea-AI Summary

Selecta Biosciences, Inc. (NASDAQ: SELB) announced a conference call scheduled for May 13, 2021, at 8:30 a.m. ET to discuss its financial results for Q1 2021 and provide a business update. The company is focused on leveraging its ImmTOR™ platform to develop therapies targeting unwanted immune responses. Selecta's pipeline includes enzyme therapies, gene therapies, and treatments for autoimmune diseases, showcasing its potential to enhance biologic therapies and restore self-tolerance. Investors can access the call via phone or through the company's website.

Positive

• Selecta's ImmTOR™ platform may enhance the efficacy of biologic therapies.
• The pipeline includes focused programs in enzyme and gene therapies.
• Potential restoration of self-tolerance in autoimmune diseases.

Negative

• None.

WATERTOWN, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that that it plans to host a conference call on Thursday, May 13, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2021 and provide a business update.

Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10147801. Investors and the public can access the live and archived webcast of this call and a copy of the presentation via the Investors & Media section of the company’s website, www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media: 
Meredith Sosulski, Ph.D.
LifeSci Communications, LLC
+1-929-469-3851
msosulski@lifescicomms.com

FAQ

When will Selecta Biosciences announce its Q1 2021 financial results?

Selecta Biosciences will announce its Q1 2021 financial results on May 13, 2021.

What is the focus of Selecta Biosciences' ImmTOR™ platform?

Selecta Biosciences' ImmTOR™ platform focuses on developing tolerogenic therapies to mitigate unwanted immune responses.

How can investors participate in the Selecta Biosciences conference call?

Investors can participate in the conference call by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international).

Where can I find the webcast of Selecta Biosciences' financial results call?

The webcast of the financial results call can be accessed on Selecta Biosciences' website under the Investors & Media section.